The Pharmacy Times® Breast Cancer resource center provides clinical news and articles, coverage from conferences and meetings, links to condition-specific resources, and videos and other content.
What can we help you find?
Study: Liquid Biopsies a Possible Method for Improved Breast Cancer Detection, Monitoring Progression
Genomic profiles measured through circulating free DNA in the blood of patients with breast cancer may provide a more effective way to treat the disease and track its progression.
Researchers examine how stem cells promote neuronal growth in tissue regeneration and in cancer progression.
Researchers Report Positive Preliminary Data, Favorable Safety Update for Pelareorep in Breast Cancer
The researchers plan to present updated data at the European Society for Medical Oncology Breast Cancer conference in May.
New information from the IQVIA “Global Medicine Spending and Usage Trends” report highlights the expected growth of specialty pharmacy spending by 2024.
DCIS is a noninvasive condition in which abnormal cells are found in the lining of a breast duct but have not spread to other tissues in the breast.
New research has examined the details surrounding the signaling molecule interleukin-2, which could lead to more targeted therapies for diseases such as cancer.
Study: Genetic Testing Recommended for Some Postmenopausal Women with Breast Cancer, No Hereditary Risk Factors
Guidelines recommend that Ashkenazi Jewish women discuss genetic testing with physicians, but other women with breast cancer are less likely to receive a recommendation of testing.
Research may lead to the development of new types of binding proteins for biological sugar structures, which play a significant role in cancer and infectious diseases.
Patients with a history of cancer have a greater likelihood of developing atrial fibrillation, the most common heart rhythm disorder, compared with the general population.
The new study has found that the lymphedema monitoring technology, marketed by LymphaTech, can effectively detect early arm swelling associated with lymphedema in breast cancer patients.
Trastuzumab-dttb was first approved in January 2019 across all eligible indications, mainly adjuvant treatment of HER2-overexpressing breast cancer, metastatic breast cancer, and metastatic gastric cancer.
The growth of the pipeline has led to increases in insurance carriers’ specialty plan spend.